SAB Biotherapeutics, Inc. (SABS)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Immunotheraphies	2.24M
Immunotheraphies Growth	-90.63%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
United States	2.24M
United States Growth	-90.63%